Study details
Enrolling now
Axitinib and Ipilimumab for Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT IDNCT04996823ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
25
Study length
about 5.7 years
Ages
18+
Locations
1 site in FL
About this study
This trial is testing if taking axitinib with ipilimumab is effective in treating advanced melanoma. The treatment involves medication. Adults will be enrolled, and its length is 2063 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Axitinib
- 2.Take Ipilimumab
PhasePhase 2
DrugAxitinib
Routeoral
Primary goalOverall Response Rate
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
axitinib, ipilimumab (Immune checkpoint inhibitor; blocks CTLA-4 on T cells)
Drug routes
oral (Oral Tablet), injection (Injection)
Endpoints
Primary: Overall Response Rate
Secondary: Clinical Benefit Rate, Duration of Response, Overall Survival, Progression Free Survival
Body systems
Oncology